Humanized anti-claudin-1 antibodies and uses thereof
US11365251B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 27, 2020 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Oct 27, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/567
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs). Thus, the present invention relates to humanized anti-claudin-1 antibodies and uses thereof, in particular for the prevention and treatment of hepatitis C virus infection, virus-induced liver diseases, hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.